CDKN2A and neoplasm: Acquisition of further mutations, mainly occurring in the p53, CDKN2A, SMAD4, CDK27, p16, BRCA1, and BRCA2 genes [3,4], lead to general oncogenic activity associated with unrestrained proliferation of tumor cells, invasive tumor growth, metastasis, and development of chronic inflammation.